{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:35:54Z","timestamp":1774870554871,"version":"3.50.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.critrevonc.2015.12.016","type":"journal-article","created":{"date-parts":[[2016,1,3]],"date-time":"2016-01-03T15:54:39Z","timestamp":1451836479000},"page":"214-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: Peripheral T-cell lymphomas"],"prefix":"10.1016","volume":"99","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayveer","family":"Bonthapally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lutes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.12.016_bib0005","series-title":"Full Prescribing Information","author":"ADCETRIS\u00ae (brentuximab vedotin) for injection","year":"2015"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0010","series-title":"Summary of Product Characteristics","author":"ADCETRIS\u00ae 50\u2009mg powder for concentrate for solution for infusion","year":"2015"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.016_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10637-012-9889-4","article-title":"Gemcitabine alone and\/or containing chemotherapy is efficient in refractory or relapsed NK\/T-cell lymphoma","volume":"31","author":"Ahn","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/fon.10.83","article-title":"Forodesine: review of preclinical and clinical data","volume":"6","author":"Al-Kali","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0030","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/OTT.S30773","article-title":"Profile of panobinostat and its potential for treatment in solid tumors: an update","volume":"6","author":"Anne","year":"2013","journal-title":"Onco Targets Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the royal marsden hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0040","series-title":"Full prescribing information. Revised: 7\/2014","author":"BELEODAQ\u00ae (belinostat) for injection, for intravenous administration","year":"2015"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0045","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II Intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0055","first-page":"1971","article-title":"Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"7","author":"Bodiford","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0060","series-title":"Injection for intravenous use. Full prescribing information. Revised: 9\/","author":"Campath\u00ae (alemtuzumab)","year":"2015"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0065","first-page":"45","article-title":"Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin","volume":"7","author":"Chen","year":"2013","journal-title":"Onco Targets Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2015.12.016_bib0070","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1349-7006.2012.02373.x","article-title":"Increase in incidence of adult T-cell leukemia\/lymphoma in non-endemic areas of Japan and the United States","volume":"103","author":"Chihara","year":"2012","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0085","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.016_bib0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0095","unstructured":"Dearden C., Johnson R., Pettengell R., et al., 2015. British Committee for Standards in Haematology (BCSH) guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Updated August 2013. Available at: http:\/\/www.bcshguidelines.com. (accessed 06.02.15.)."},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.016_bib0100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12032-009-9313-x","article-title":"Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP","volume":"27","author":"Dincol","year":"2010","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","article-title":"Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma","volume":"30","author":"Dong","year":"2013","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0110","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2015.12.016_bib0115","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3097.3097","article-title":"A dose finding lead-in study of E7777 (diphtheria toxin fragment-interleukin-2 fusion protein) in persistent or recurrent cutaneous T-cell lymphoma (CTCL)","volume":"124","author":"Duvic","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","article-title":"Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma","volume":"5","author":"Emmanouilides","year":"2004","journal-title":"Clin. Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0130","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.12488","article-title":"A phase I\/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas","volume":"163","author":"Evens","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0140","series-title":"Solution for intravenous injection. Full prescribing information. Revised: 5\/2012","author":"FOLOTYN\u00ae (pralatrexate injection)","year":"2012"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1744.1744","article-title":"A Phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-Cell lymphomas","volume":"124","author":"Fanale","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2015.12.016_bib0150","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.12.016_bib0155","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","article-title":"Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma","volume":"2","author":"Foss","year":"2014","journal-title":"Biomarkers Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0165","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0175","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0180","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4342.4342","article-title":"Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies","volume":"122","author":"Gambacorti-Passerini","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0185","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2013.08.016","article-title":"Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation","volume":"89","author":"Gkotzamanidou","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0190","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.503.503","article-title":"A Phase 2 Study of panobinostat (PAN) in combination with bortezomib (BTZ) in patients with relapsed\/refractory peripheral T-cell lymphoma (PTCL) or NK\/T-cell lymphoma (NKL)","volume":"124","author":"Goh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.2014.876407","article-title":"Novel therapies for cutaneous T-cell lymphoma: what does the future hold?","volume":"23","author":"Guenova","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.016_bib0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2015.12.016_bib0210","first-page":"147","article-title":"Belinostat in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): results from the pivotal BELIEF trial","volume":"31","author":"Horwitz","year":"2013","journal-title":"Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2015.12.016_bib0215","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0220","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0225","series-title":"Full prescribing information. Revised: 10\/2014","author":"ISTODAX\u00ae (romidepsin) for injection","year":"2015"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0230","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0235","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0240","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2758.2758","article-title":"Novel imaging modalities in innovative xenograft mouse model of T-cell lymphoma confirm marked synergy of romidepsin and pralatrexate","volume":"120","author":"Jain","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","article-title":"The changing landscape of peripheral T-cell lymphoma in the era of novel therapies","volume":"51","author":"Karlin","year":"2014","journal-title":"Semin. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol. Int."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0255","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/17474086.2013.814833","article-title":"Romidepsin for peripheral T-cell lymphoma","volume":"6","author":"Khot","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.016_bib0260","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2013.815165","article-title":"Panobinostat in lymphoid and myeloid malignancies","volume":"22","author":"Khot","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0265","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdn726","article-title":"Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study","volume":"20","author":"Kim","year":"2009","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0270","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.396.396","article-title":"The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed\/refractory non Hodgkin's lymphoma (NHL)","volume":"124","author":"Kuruvilla","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2015.12.016_bib0275","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study","volume":"80","author":"L\u00f3pez","year":"2008","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.016_bib0285","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11864-013-0232-x","article-title":"Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?","volume":"14","author":"Lunning","year":"2013","journal-title":"Curr. Treat. Options Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2015.12.016_bib0290","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2015.12.016_bib0295","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.critrevonc.2015.12.016_bib0300","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.016_bib0305","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bmt.1701592","article-title":"Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma","volume":"23","author":"Mayer","year":"1999","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0310","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/07357900600814490","article-title":"Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"24","author":"Mey","year":"2006","journal-title":"Cancer Invest."},{"issue":"13","key":"10.1016\/j.critrevonc.2015.12.016_bib0315","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0320","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0325","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0330","unstructured":"National Cancer Institute, 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non-Hodgkin's Lymphomas. Version 2.2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. (accessed 10.11.15.)."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0335","unstructured":"National Cancer Institute, 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Multiple Myeloma. Version 2.2016. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#sire. (accessed 10.11.15.)."},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0340","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","article-title":"Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma","volume":"92","author":"Ng","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2015.12.016_bib0345","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.016_bib0350","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2015.12.016_bib0355","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0360","series-title":"Full prescribing information. Revised: August 2011","author":"ONTAK\u00ae (denileukin diftitox) injection for intravenous infusion","year":"2014"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.12.016_bib0365","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1349-7006.2012.02287.x","article-title":"Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T\/natural killer-cell malignanciese","volume":"103","author":"Ogura","year":"2012","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2015.12.016_bib0370","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/cas.12435","article-title":"Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma","volume":"105","author":"Ogura","year":"2014","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.016_bib0375","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.016_bib0380","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2013.11.002","article-title":"Autologous stem cell transplantation for T-cell lymphomas","volume":"51","author":"Perrone","year":"2014","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0390","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/17474086.2013.814437","article-title":"Current state of art for transplantation paradigms in peripheral T-cell lymphomas","volume":"6","author":"Perrone","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"Suppl. 5s","key":"10.1016\/j.critrevonc.2015.12.016_bib0395","article-title":"Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator\u2019s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)","volume":"32","author":"Phillips","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2015.12.016_bib0400","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2015.12.016_bib0405","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.critrevonc.2015.12.016_bib0410","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0415","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1809.1809","article-title":"Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"122","author":"Pro","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0420","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3095.3095","article-title":"Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"124","author":"Pro","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0425","series-title":"Full prescribing information. Revised: 9\/2014","author":"REVLIMID\u00ae (lenalidomide) capsules, for oral us","year":"2015"},{"issue":"32","key":"10.1016\/j.critrevonc.2015.12.016_bib0430","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0435","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.368.368","article-title":"High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients","volume":"122","author":"Redaelli","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0440","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminhematol.2013.11.006","article-title":"Chemotherapeutic advancements in peripheral T-cell lymphoma","volume":"51","author":"Reddy","year":"2014","journal-title":"Semin. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.016_bib0445","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2012.069757","article-title":"Multicenter phase II study of plitidepsin in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma","volume":"98","author":"Ribrag","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0450","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0455","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3075.3075","article-title":"Safe and effective treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and low baseline platelet counts with belinostat","volume":"124","author":"Savage","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0460","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2013.11.010","article-title":"Allogeneic transplantation in T-cell lymphomas","volume":"51","author":"Schmitz","year":"2014","journal-title":"Semin. Hematol."},{"issue":"15","key":"10.1016\/j.critrevonc.2015.12.016_bib0465","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/cncr.26700","article-title":"Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973\u20132008","volume":"118","author":"Sharaiha","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0470","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14656566.2013.770474","article-title":"Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma","volume":"14","author":"Shimanovsky","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0475","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4483.4483","article-title":"Phase 1 study of MLN8237, an aurora kinase A (AURKA) inhibitor, combined with vorinostat, a histone deacetylase (HDAC) inhibitor, in lymphoid malignancies","volume":"124","author":"Siddiqi","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0480","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice","volume":"42","author":"Sirotnak","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.016_bib0485","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","article-title":"Mogamulizumab: first global approval","volume":"72","author":"Subramaniam","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0490","series-title":"World Health Organization Classification of Tumours","article-title":"Pathology and genetics of tumours of hematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0495","series-title":"Full prescribing information. Revised: 9\/2013","author":"TREANDA\u2122 (bendamustine HCL) injection","year":"2015"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.016_bib0500","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.016_bib0505","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0510","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2015.12.016_bib0515","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.016_bib0520","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.016_bib0525","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","article-title":"A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"51","author":"Weidmann","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0530","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.016_bib0535","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0540","series-title":"Full prescribing information. Revised: 5\/2014","author":"XALKORI\u00ae (crizotinib) capsules, oral","year":"2015"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.016_bib0545","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci."},{"issue":"33","key":"10.1016\/j.critrevonc.2015.12.016_bib0550","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group studye","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.016_bib0555","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2015.12.016_bib0560","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0565","series-title":"Full prescribing information. Revised: 04\/2013","author":"ZOLINZA\u00ae (vorinostat) Capsules","year":"2015"},{"key":"10.1016\/j.critrevonc.2015.12.016_bib0570","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"14","author":"Zelenetz","year":"2003","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2015.12.016_bib0575","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2015.12.016_bib0580","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.016_bib0585","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.016_bib0590","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.016_bib0595","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.016_bib0600","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2011.629701","article-title":"Overview of alemtuzumab therapy for the treatment of T-cell lymphomas","volume":"53","author":"Zinzani","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.016_bib0605","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1763.1763","article-title":"A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral T-cell lymphoma (PTCL)","volume":"124","author":"Zinzani","year":"2014","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815301062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815301062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T09:31:32Z","timestamp":1599989492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815301062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":121,"alternative-id":["S1040842815301062"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.016","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: Peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}